Last Updated: June 25, 2026

Patent: 10,279,014

✉ Email this page to a colleague

Summary for Patent: 10,279,014

Title:	Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
Abstract:	A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.
Inventor(s):	Khalili; Kamel (Bala Cynwyd, PA), Malcolm; Thomas (Bedminster, NJ), Kohn; Kenneth I. (West Bloomfield, MI)
Assignee:	Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown)
Application Number:	15/864,309
Patent Claims:	see list of patent claims

Details for Patent 10,279,014

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	10,279,014	2038-01-08
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,279,014	2038-01-08
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	October 27, 2003	10,279,014	2038-01-08
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	November 23, 2004	10,279,014	2038-01-08
Bristol-myers Squibb Company	NULOJIX	belatacept	For Injection	125288	June 15, 2011	10,279,014	2038-01-08
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388	August 19, 2011	10,279,014	2038-01-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.